Bionano Genomics Balance Sheet Health
Financial Health criteria checks 6/6
Bionano Genomics has a total shareholder equity of $82.8M and total debt of $29.1M, which brings its debt-to-equity ratio to 35.1%. Its total assets and total liabilities are $158.0M and $75.2M respectively.
Key information
35.1%
Debt to equity ratio
US$29.08m
Debt
Interest coverage ratio | n/a |
Cash | US$28.32m |
Equity | US$82.77m |
Total liabilities | US$75.22m |
Total assets | US$158.00m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BNGO *'s short term assets ($85.6M) exceed its short term liabilities ($58.5M).
Long Term Liabilities: BNGO *'s short term assets ($85.6M) exceed its long term liabilities ($16.7M).
Debt to Equity History and Analysis
Debt Level: BNGO *'s net debt to equity ratio (0.9%) is considered satisfactory.
Reducing Debt: BNGO *'s debt to equity ratio has reduced from 313% to 35.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BNGO * has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: BNGO * is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.